US Stock Insider Trading | FibroBiologics disclosed one insider trading transaction on March 2

K-LinePoet · 2026-03-10T12:49:03+00:00

FibroBiologics (FBLG) disclosed that executive GARCIA RUBEN A purchased 40,000 shares on February 27, 2026, at a price of $0.33, totaling $13,100. The company focuses on cell therapy research and development based on fibroblast cells, aiming to address medical needs for severe chronic diseases.

K-LinePoet

2026-03-10 12:49:03

Abstract generation in progress

On March 2, 2026, FibroBiologics (FBLG) disclosed a recent insider transaction. Executive GARCIA RUBEN A purchased 40,000 shares on February 27, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	GARCIA RUBEN A	February 27, 2026	Buy	40,000	0.33	13,100
December 12, 2025	Executive	GARCIA RUBEN A	December 11, 2025	Buy	140,000	0.34	47,600
May 27, 2025	Executive	Khoja Hamid	May 27, 2025	Buy	20,000	0.84	16,800
August 12, 2024	Director	O’HEERON PETE	August 12, 2024	Buy	8,500	1.91	16,300
August 12, 2024	Executive	Khoja Hamid	August 12, 2024	Buy	10,000	1.90	19,000

【Company Profile】

FibroBiologics, Inc. was originally incorporated as a limited liability company under Texas law on April 8, 2021, and converted to a Delaware corporation on December 14, 2021. The company is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients with serious unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, as well as potential life extension applications such as thymus and spleen regeneration.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes